Melbourne, Australia – 9 July 2018 – Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial research and development company focused on pain mitigation in wounds for humans and animals, announces that its wholly owned subsidiary, Animal Ethics Pty Ltd (Animal Ethics), has successfully received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) to extend the use of Tri-Solfen® in Australia to include pain relief for beef and dairy calves.
Anthony (Bim) Struss, President of AgForce Cattle Board, Councillor of the Cattle Council Australia and Member of the Queensland Animal Welfare Advisory Board, commented:
“We have seen widespread use of Tri-Solfen® across the beef cattle industry since the initial registration of the product in cattle in 2014 and we welcome this extended use. Farmers are increasingly seeking a way to improve welfare standards and Tri-Solfen® provides a safe and effective way to reduce pain and improve wound healing more broadly across livestock.”
Kathryn Davis, Program Leader, Animal Health & Fertility at Dairy Australia, commented:
“This is great news for dairy calf welfare. It is now easy for farmers to provide cheap and effective pain relief on site for calves following husbandry procedures.”
Tri-Solfen® is an innovative spray and stay topical local anaesthetic and antiseptic gel that is designed to adhere to wounds to provide rapid onset numbing with prolonged analgesia effects. It also contains active ingredients designed to minimise bleeding, protect against infection, coat the wound and promote healing.
Tri-Solfen® was approved in lambs in 2004, becoming the first topical local anaesthetic pain relief product specifically developed and approved for on-farm use to address husbandry-related pain in infant livestock. Since then, the product has been approved for use in beef calves, and has been widely adopted by Australian farmers in what has become a revolution in farm animal welfare, with over eight million lambs and one million calves treated with the pain relief product each year.
With over one billion livestock animals globally undergoing highly invasive painful husbandry procedures annually, and a critical shortage of products available for on-farm pain alleviation, Animal Ethics is continuing its drive to deliver solutions by pursuing extensions of use for different species, for an increasing range of wound applications, as well as expanding to international markets. The process for securing a European registration for Tri-Solfen® through the Group’s partner, Dechra Veterinary Products, an international specialist veterinary pharmaceutical company, began last month with a dossier being submitted to the European Medicines Agency for painful husbandry procedures in piglets and dairy calves to be treated with the proven technology.
Tri-Solfen® is already registered in Australia separately for pain alleviation in sheep and cattle husbandry procedures, where it is marketed and distributed by Bayer Animal Health, a global leader in animal health. To date, Tri-Solfen® has been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries.
Allan Giffard, Managing Director of Medical Ethics, added:
“Animal Ethics is proud to be part of the global movement to address animal pain. Not only does Tri-Solfen® deliver improved welfare, but farmers report, that they also notice the big impact on productivity. Tri-Solfen® is proven to deliver a highly effective, practical and cost-efficient solution to improve animal welfare outcomes. This label extension is another important step for Medical Ethics as we continue to build the value of the brand by expanding the indications for which our products are used and our international reach. We are continuing to make good progress towards the registration of Tri-Solfen® in Europe with our partner, Dechra Veterinary Products. We are also committed to investing for long term sustainable growth and further develop our recognised technology in humans. I look forward to providing an update on this in due course.”
– Ends –
Medical Ethics Pty Ltd
Allan Giffard, Managing Director
Charles Olsson, Marketing Director
Tel: +61 419 362 286
Brett Pollard / Victoria Foster Mitchell
Tel: +44 20 3727 1000
Notes for editors:
About Medical Ethics Pty Ltd
Medical Ethics Pty Ltd is a commercial research and development company focused on pain mitigation in wounds for humans and animals. Our vision is to develop and deliver our highly effective, safe, affordable and practical pain relief products to prevent pain and minimise suffering associated with wounds in humans, livestock and companion animals. Medical Ethics is focused on the development of the Group’s patented technology initially for the treatment of chronic wounds such as diabetic leg ulcers. Animal Ethics, a wholly owned subsidiary of Medical Ethics, is the first, and currently the only, company globally to develop, launch and commercialise a topical pain and wound management product for use in livestock undergoing painful husbandry procedures.
In March 2017, Medical Ethics secured investment from Dechra Pharmaceuticals PLC (Dechra) in exchange for a 33% shareholding in the Group. A separate global license agreement (excluding Australia and NZ) was entered into by Dechra and Animal Ethics to secure the marketing and distribution rights of the Group’s proprietary platform technology in animals.
Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts to immediately numb the wound with long lasting analgesic effect. It also acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.
The global market potential for Tri-Solfen® is estimated to be in excess of AUD $350 million per year for the treatment of routine on farm procedures in calves, lambs and piglets.
Allan Giffard, Managing Director
+61 419 362 286
+61 432 344 069
Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000